Colleen Kusy
Stock Analyst at Baird
(0)
# 4720
Out of 5,308 analysts
53
Total ratings
21.62%
Success rate
-24.38%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
OCS Oculis Holding | Maintains: Outperform | 37 41 | 16.18 | 153.4% | 4 | Mar 13, 2025 | |
AGEN Agenus | Maintains: Neutral | 6 3 | 1.73 | 73.41% | 2 | Mar 12, 2025 | |
CHRS Coherus BioSciences | Maintains: Outperform | 4 6 | 0.79 | 659.49% | 5 | Dec 5, 2024 | |
ELVN Enliven Therapeutics | Maintains: Outperform | 32 40 | 16.47 | 142.87% | 2 | Nov 15, 2024 | |
SYRE Spyre Therapeutics | Maintains: Outperform | 50 65 | 13.36 | 386.53% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 92 55 | 19.61 | 180.47% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 3 | 0.29 | 934.48% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 18 17 | 6.84 | 148.54% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 27 25 | 4.64 | 438.79% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 105 | 64.86 | 61.89% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 40 | n/a | n/a | 3 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 15 | n/a | n/a | 1 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 255 210 | 4.31 | 4772.39% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 34 | 3.26 | 942.94% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 230 | 1.23 | 18599.19% | 1 | Nov 2, 2021 |